Oryzon Genomics S.a.

Geadic Biotec, Aie

Tamara Maes

Cristina Mascaro Crusat

Alberto Ortega Muñoz

Elena Carceller González

Serena Lunardi

Matthew Colin Thor Fyfe

Marc Martinell Pedemonte

Olga Durany Turk

Julio Castro Palomino

Jonathan Alleman Baker

Andreas Doll

Cristina Perez

Antonio Gil Moreno

Jaume Reventós Puigjaner

Elisabet Rossell

Carlos Buesa Arjol

Marta Barrachina Castillo

Isidro Ferrer Abizanda

Fiona Mack

William E Pierceall

Mark D Demario

David Rotllant Pozo

Cristina Mascarò Crusat

Inigo Tirapu Fernandez De La Cuesta

Filippo Ciceri

Miguel Abal Posada

Elena Aibar Duran

Elena Aibar Durán

Jaume REVENTÓS Puigjaner

Christian GRIÑÁN Ferre

Mercè PALLÀS Lliberia

Roser Nadal Alemany

Antonio Armario GARCÍA

Elena Carceller GONZÁLEZ

Alberto Ortega MUÑOZ

Mark Demario

Jaume Reventos Puigjaner

Cristina Mascaró Crusat

The invention relates to methods to determine KDM1A target engagement and chemoprobes useful therefor. In particular, the invention relates to non-peptidic KDM1A chemoprobes carrying a tag or label that can be used to assess KDM1A target engagement in cells and tissues. These chemoprobes can also be used to identify KDM1A interacting factors and analyze expression levels of KDM1A.

Methods to determine KDM1A target engagement and chemoprobes useful therefor

The instant invention relates to combinations of the compound of formula (I) or pharmaceutically acceptable salts thereof with other active pharmaceutical ingredients pharmaceutical compositions comprising them, and their use as medicaments, particularly for the treatment of hematological malignancies.

Combinations of LSD1 inhibitors for the treatment of hematological malignancies

Provided herein are methods for treating multiple sclerosis using (&#x2212;) 5-((((trans)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine, or a pharmaceutically acceptable salt or solvate thereof.

Method of treating multiple sclerosis employing a LSD1-inhibitor

The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharmaceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC).

Combinations of LSD1 inhibitors for use in the treatment of solid tumors

The invention relates to methods and compositions for the treatment or prevention of diseases and disorders associated with myeloproliferative disorders. In particular, the invention relates to an LSD 1 inhibitor for use in treating or preventing Philadelphia chromosome negative myeloproliferative disorders.

Lysine demethylase inhibitors for myeloproliferative disorders

The invention relates to the surprising finding that biomarkers corresponding to ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1 R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, S0CS2, and DCN are differentially expressed in control samples as compared to samples from patients having endometrial cancer and are therefore useful for detecting endometrial cancer. In particular these biomarkers having excellent sensitivity, specificity, and/or the ability to separate affected from non affected individuals. Furthermore, the inventors found that the differential expression of these biomarkers in primary endometrial cancer tumor tissue is correlated to their expression level in uterine fluid samples as compared to control values. Thus these biomarkers are robust in that they are found to be differentially expressed in several different types of samples from affected individuals.

Markers for endometrial cancer

The present invention describes methods of molecular diagnosis of a concrete form of a-synucleinopathy, the dementia with Lewy bodies (DLB), associated to the levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) or the alteration of its ubiquityl-ligase activity. It also refers to the use of compounds that permit the modification of the UCH-L1 levels or of the enzymatic activity of UCH-L1. This invention has application in the diagnosis and treatment of patients suffering from DLB.

Molecular diagnostic method for dementia with lewy bodies

Growing community of inventors

Castelldefels, Spain

Tamara Maes